The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
Open accessAbstract
Introduction: Of the more than one million global cases of breast cancer diagnosed each year, approximately fifteen percent are characterized as triple-negative, lacking the estrogen, progesterone, and Her2/neu receptors. Lack of effective therapies, younger age at onset, and early metastatic spread have contributed to the poor prognoses and outcomes associated with these malignancies. Here, we investigate the ability of the histone deacetylase inhibitor panobinostat (LBH589) to selectively target triple-negative breast cancer (TNBC) cell proliferation and survival in vitro and tumorigenesis in vivo. Methods: TNBC cell lines MDA-MB-157, MDA-MB-231, MDA-MB-468, and BT-549 were treated with nanomolar (nM) quantities of panobinostat. Relevant histone acetylation was verified by flow cytometry and immunofluorescent imaging. Assays for trypan blue viability, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) proliferation, and DNA fragmentation were used to evaluate overall cellular toxicity. Changes in cell cycle progression were assessed with propidium iodide flow cytometry. Additionally, qPCR arrays were used to probe MDA-MB-231 cells for panobinostat-induced changes in cancer biomarkers and signaling pathways. Orthotopic MDA-MB-231 and BT-549 mouse xenograft models were used to assess the effects of panobinostat on tumorigenesis. Lastly, flow cytometry, ELISA, and immunohistochemical staining were applied to detect changes in cadherin-1, E-cadherin (CDH1) protein expression and the results paired with confocal microscopy in order to examine changes in cell morphology. Results: Panobinostat treatment increased histone acetylation, decreased cell proliferation and survival, and blocked cell cycle progression at G2/M with a concurrent decrease in S phase in all TNBC cell lines. Treatment also resulted in apoptosis induction at 24 hours in all lines except the MDA-MB-468 cell line. MDA-MB-231 and BT-549 tumor formation was significantly inhibited by panobinostat (10 mg/kg/day) in mice. Additionally, panobinostat up-regulated CDH1 protein in vitro and in vivo and induced cell morphology changes in MDA-MB-231 cells consistent with reversal of the mesenchymal phenotype. Conclusions: This study revealed that panobinostat is overtly toxic to TNBC cells in vitro and decreases tumorigenesis in vivo. Additionally, treatment up-regulated anti-proliferative, tumor suppressor, and epithelial marker genes in MDA-MB-231 cells and initiated a partial reversal of the epithelial-to-mesenchymal transition. Our results demonstrate a potential therapeutic role of panobinostat in targeting aggressive triple-negative breast cancer cell types.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J.-P., Tong, F., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,188
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Prat, A., Parker, J. S., Karginova, O., Fan, C., Livasy, C., Herschkowitz, J. I., He, X., & Perou, C. M. (2010) · Breast Cancer Research · doi:10.1186/bcr2635 · Cited by 2,167
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542
Histone Deacetylase Inhibitors: Overview and Perspectives
Dokmanovic, M., Clarke, C., & Marks, P. A. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0324 · Cited by 1,164
Epithelial—mesenchymal and mesenchymal—epithelial transitions in carcinoma progression
Hugo, H., Ackland, M. L., Blick, T., Lawrence, M. G., Clements, J. A., Williams, E. D., & Thompson, E. W. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21223 · Cited by 1,091
Kenny, P. A., Lee, G. Y., Myers, C. A., Neve, R. M., Semeiks, J. R., Spellman, P. T., Lorenz, K., Lee, E. H., Barcellos‐Hoff, M. H., PETERSEN, O. W., et al. (2008) · eScholarship (California Digital Library) · Cited by 1,039
Triple-Negative Breast Cancer: An Unmet Medical Need
Hudis, C. A., & Gianni, L. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-s1-01 · Cited by 780
Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer
Anders, C. K., & Carey, L. A. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.s.008 · Cited by 625
CLINICAL DEVELOPMENT OF HISTONE DEACETYLASE INHIBITORS AS ANTICANCER AGENTS
Drummond, D. C., Noble, C. O., Kirpotin, D. B., Guo, Z., Scott, G. K., & Benz, C. C. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095825 · Cited by 494
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39104c1 · Cited by 465
Triple-Negative Breast Cancer: Risk Factors to Potential Targets
Schneider, B. P., Winer, E. P., Foulkes, W. D., Garber, J., Perou, C. M., Richardson, A., Sledge, G. W., & Carey, L. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1208 · Cited by 437
Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
Atadja, P. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.019 · Cited by 419
Catley, L., Weisberg, E., Kiziltepe, T., Tai, Y.-T., Hideshima, T., Neri, P., Tassone, P., Atadja, P., Chauhan, D., Munshi, N. C., et al. (2006) · Blood · doi:10.1182/blood-2006-04-016055 · Cited by 336
May, C. D., Sphyris, N., Evans, K. W., Werden, S. J., Guo, W., & Mani, S. A. (2011) · Breast Cancer Research · doi:10.1186/bcr2789 · Cited by 333
Epithelial mesenchymal transition traits in human breast cancer cell lines
Blick, T., Widodo, E., Hugo, H., Waltham, M., Lenburg, M. E., Neve, R. M., & Thompson, E. W. (2008) · Clinical & Experimental Metastasis · doi:10.1007/s10585-008-9170-6 · Cited by 314
Zajchowski, D. A., Bartholdi, M. F., Gong, Y., Webster, L., Liu, H.-L., Munishkin, A. V., Beauheim, C., Harvey, S., Ethier, S. P., & Johnson, P. H. (2001) · PubMed · Cited by 314
Giles, F., Fischer, T., Cortes, J., Garcia-Manero, G., Beck, J., Ravandi, F., Masson, E., Rae, P., Laird, G., Sharma, S., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0511 · Cited by 312
Histone deacetylase inhibitors in cancer treatment
Vigushin, D. M., & Coombes, R. C. (2002) · Anti-Cancer Drugs · doi:10.1097/00001813-200201000-00001 · Cited by 301
Ellis, L., Pan, Y., Smyth, G. K., George, D. J., McCormack, C., Williams-Truax, R., Mita, M., Beck, J., Burris, H., Ryan, G., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4262 · Cited by 297
Differentiation state and invasiveness of human breast cancer cell lines
Sommers, C. L., Byers, S. W., Thompson, E. W., Torri, J. A., & Gelmann, E. P. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00666165 · Cited by 270
Triple-Negative Breast Cancer: A Short Review
Elias, A. D. (2010) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3181b8afcf · Cited by 242
Targeting histone deacetylase in cancer therapy
Lin, H., Chen, C., Lin, S., Weng, J., & Chen, C. (2006) · Medicinal Research Reviews · doi:10.1002/med.20056 · Cited by 241
Chacón, R. D., & Costanzo, M. V. (2010) · Breast Cancer Research · doi:10.1186/bcr2574 · Cited by 239
Cadherin-11 is expressed in invasive breast cancer cell lines.
Pishvaian, M. J., Feltes, C. M., Thompson, P., Bussemakers, M. J. G., Schalken, J. A., & Byers, S. W. (1999) · PubMed · Cited by 238
Maiso, P., Carvajal-Vergara, X., Ocio, E. M., López-Pérez, R., Mateo, G., Gutiérrez, N., Atadja, P., Pandiella, A., & San Miguel, J. F. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4186 · Cited by 238
Histone deacetylase inhibitors: Multifunctional anticancer agents
Liu, T., Kuljaca, S., Tee, A., & Marshall, G. M. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2005.12.006 · Cited by 230
Three-Dimensional Cell Growth Confers Radioresistance by Chromatin Density Modification
Storch, K., Eke, I., Borgmann, K., Krause, M., Richter, C., Becker, K., Schröck, E., & Cordes, N. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3848 · Cited by 192
Treatment of triple negative breast cancer (TNBC): current options and future perspectives
De Laurentiis, M., Cianniello, D., Caputo, R., Stanzione, B., Arpino, G., Cinieri, S., Lorusso, V., & De Placido, S. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)70025-6 · Cited by 184
Drasin, D. J., Robin, T. P., & Ford, H. L. (2011) · Breast Cancer Research · doi:10.1186/bcr3037 · Cited by 168
Palmieri, D., Lockman, P. R., Thomas, F. C., Hua, E., Herring, J., Hargrave, E., Johnson, M., Flores, N., Qian, Y., Vega-Valle, E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1039 · Cited by 164
Geng, L., Cuneo, K. C., Fu, A., Tu, T., Atadja, P. W., & Hallahan, D. E. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0049 · Cited by 163
The Tumor-Suppressor Function of E-Cadherin
Semb, H., & Christofori, G. (1998) · The American Journal of Human Genetics · doi:10.1086/302173 · Cited by 161
Zhou, Q., Atadja, P., & Davidson, N. E. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.1.3549 · Cited by 160
Prince, H. M., Bishton, M. J., & Johnstone, R. W. (2009) · Future Oncology · doi:10.2217/fon.09.36 · Cited by 131
Crisanti, M. C., Wallace, A. F., Kapoor, V., Vandermeers, F., Dowling, M. L., Pereira, L. P., Coleman, K. A., Campling, B. G., Fridlender, Z. G., Kao, G. D., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0138 · Cited by 124
Kuniyasu, H., Ellis, L. M., Evans, D. B., Abbruzzese, J. L., Fenoglio, C. J., Bucana, C. D., Cleary, K. R., Tahara, E., & Fidler, I. J. (1999) · PubMed · Cited by 124
Thomas, S., Thurn, K. T., Biçaku, E., Marchion, D. C., & Münster, P. N. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1364-y · Cited by 114
Rao, R., Balusu, R., Fiskus, W. C., Mudunuru, U., Venkannagari, S., Chauhan, L., Smith, J. E., Hembruff, S. L., Ha, K., Atadja, P. W., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0979 · Cited by 112
Rathkopf, D. E., Wong, B. Y., Ross, R. W., Anand, A., Tanaka, E., Woo, M. M., Hu, J. R., Dzik-Jurasz, A., Yang, W., & Scher, H. I. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1289-x · Cited by 111
Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence
Rhodes, L. V., Muir, S. E., Elliott, S. G., Guillot, L. M., Antoon, J. W., Penfornis, P., Tilghman, S. L., Salvo, V. A., Fonseca, J. P., Lacey, M. R., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0458-2 · Cited by 110
Self-citationHistone deacetylase inhibitors in the treatment of lymphoma.
Lemoine, M., & Younes, A. (2010) · PubMed · Cited by 93
Shao, W., Growney, J. D., Feng, Y., O'Connor, G., Pu, M., Zhu, W., Yao, Y.-M. M., Kwon, P. O., Fawell, S. E., & Atadja, P. W. (2010) · International Journal of Cancer · doi:10.1002/ijc.25218 · Cited by 91
Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma
Drappatz, J., Lee, E. Q., Hammond, S., Grimm, S. A., Norden, A. D., Beroukhim, R., Gerard, M., Schiff, D., S., A., Batchelor, T. T., et al. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0717-z · Cited by 81
Maiso, P., Colado, E., Ocio, E. M., Garayoa, M., Martín, J., Atadja, P. W., Pandiella, A., & Miguel, J. F. S. (2009) · Leukemia · doi:10.1038/leu.2009.182 · Cited by 70
Fazio, P. D., Schneider‐Stock, R., Neureiter, D., Okamoto, K., Wissniowski, T., Gahr, S., Quint, K., Meissnitzer, M. W., Alinger, B., Montalbano, R., et al. (2010) · Analytical Cellular Pathology · doi:10.1155/2010/847218 · Cited by 65
Novel therapeutic approaches to the treatment of metastatic breast cancer
Fernández, Y., Cueva, J. F., Palomo, A. G., Ramos, M., Juan, A. D., Calvo, L., García-Mata, J., García‐Teijido, P., Peláez, I., & García‐Estévez, L. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.10.001 · Cited by 62
Nishioka, C., Ikezoe, T., Yang, J., Komatsu, N., Bandobashi, K., Taniguchi, A., Kuwayama, Y., Togitani, K., Koeffler, H. P., & Taguchi, H. (2008) · Leukemia Research · doi:10.1016/j.leukres.2007.05.026 · Cited by 58
Cadherin–catenin complex dissociation in lobular neoplasia of the breast
Morrogh, M., de Andrade, V. P., Giri, D. D., Sakr, R. A., Paik, W., Qin, L., Arroyo, C. D., Brogi, E., Morrow, M., & King, T. A. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1860-0 · Cited by 58
Floris, G., Dêbiec‐Rychter, M., Sciot, R., Stefan, C., Fieuws, S., Machiels, K., Atadja, P. W., Woźniak, A., Faa, G., & Schöffski, P. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2588 · Cited by 58
The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression
Chen, S., Ye, J., Kijima, I., & Evans, D. B. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000917107 · Cited by 58
Catalano, M. G., Pugliese, M., Gargantini, E., Grange, C., Bussolati, B., Asioli, S., Bosco, O., Poli, R., Compagnone, A., Bandino, A., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26057 · Cited by 57
A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors
Fukutomi, A., Hatake, K., Matsui, K., Sakajiri, S., Hirashima, T., Tanii, H., Kobayashi, K., & Yamamoto, N. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9666-9 · Cited by 46
Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond
Konstantinopoulos, P. A., Karamouzis, M. V., & Papavassiliou, A. G. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.5.569 · Cited by 38
Fortunati, N., Catalano, M. G., Marano, F., Mugoni, V., Pugliese, M., Bosco, O., Mainini, F., & Boccuzzi, G. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0789-z · Cited by 25
Budman, D. R., Tai, J. Y., Calabro, A. R., & John, V. S. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9467-6 · Cited by 25
Creating zinc monkey wrenches in the treatment of epigenetic disorders
Kalin, J. H., Butler, K. V., & Kozikowski, A. P. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.05.007 · Cited by 20
Terpos, E. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.10.019 · Cited by 10
Epithelial-Mesenchymal Transition and Cancer Stem Cells
Ouyang, G. (2011) · BiblioBoard Library Catalog (Open Research Library) · doi:10.5772/19282 · Cited by 2
Cited by
Serrano-Gomez, S. J., Maziveyi, M., & Alahari, S. K. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0502-x · Cited by 814
Inhibition of histone deacetylase 1 (HDAC1) and HDAC2 enhances CRISPR/Cas9 genome editing
Liu, B., Chen, S., Rose, A. L., Chen, D., Cao, F., Zwinderman, M., Kiemel, D., Aïssi, M., Dekker, F. J., & Haisma, H. J. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkz1136 · Cited by 370
Wnt signaling in triple-negative breast cancer
Pohl, S.-G., Brook, N., Agostino, M., Arfuso, F., Kumar, A. P., & Dharmarajan, A. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.14 · Cited by 296
Yang, W., Feng, Y., Zhou, J., Cheung, O. K.-W., Cao, J., Wang, J., Tang, W., Tu, Y., Xu, L., Wu, F., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz6804 · Cited by 172
Zordoky, B. N. M., Bark, D., Soltys, C. L., Sung, M. M., & Dyck, J. R. B. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.01.023 · Cited by 98
Metadata
- Authors
- Tate, C. R., Rhodes, L. V., Segar, H. C., Driver, J. L., Pounder, F. N., Burow, M. E., & Collins-Burow, B. M.
- Venue
- Breast Cancer Research
- Published
- 2012-05-21
- Volume
- 14
- Issue
- 3
- Pages
- R79-R79
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- OpenAlex
- W2127967682
- Cited by
- 260
- References
- 61
- FWCI
- 8.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.